Search

Your search keyword '"Wu, Linda"' showing total 586 results
Start Over Author "Wu, Linda"
586 results on '"Wu, Linda"'

1. Managing OCD and Anxiety as Emerging Adults

Author

Riddle, David B., Fuselier, Madeleine N., Iacono, Julia Rose, Wu, Linda, Storch, Eric A., Kuo, Alice A, editor, Pilapil, Mariecel, editor, DeLaet, David E., editor, Peacock, Cynthia, editor, and Sharma, Niraj, editor

Published
2024
Full Text
View/download PDF

2. Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma

Author

Vithayathil, Mathew, D’Alessio, Antonio, Fulgenzi, Claudia Angela Maria, Nishida, Naoshi, Schönlein, Martin, von Felden, Johann, Schulze, Kornelius, Wege, Henning, Saeed, Anwaar, Wietharn, Brooke, Hildebrand, Hannah, Wu, Linda, Ang, Celina, Marron, Thomas U., Weinmann, Arndt, Galle, Peter R., Bettinger, Dominik, Bengsch, Bertram, Vogel, Arndt, Balcar, Lorenz, Scheiner, Bernhard, Lee, Pei-Chang, Huang, Yi-Hsiang, Amara, Suneetha, Muzaffar, Mahvish, Naqash, Abdul Rafeh, Cammarota, Antonella, Zanuso, Valentina, Pressiani, Tiziana, Pinter, Matthias, Cortellini, Alessio, Kudo, Masatoshi, Rimassa, Lorenza, Pinato, David J., and Sharma, Rohini

Published
2023
Full Text
View/download PDF

3. A meta-analysis and real-world cohort study on the sex-related differences in efficacy and safety of immunotherapy for hepatocellular carcinoma

Author

Balcar, Lorenz, Scheiner, Bernhard, Fulgenzi, Claudia Angela Maria, D’Alessio, Antonio, Pomej, Katharina, Roig, Marta Bofill, Meyer, Elias Laurin, Che, Jaekyung, Nishida, Naoshi, Lee, Pei-Chang, Wu, Linda, Ang, Celina, Krall, Anja, Saeed, Anwaar, Stefanini, Bernardo, Cammarota, Antonella, Pressiani, Tiziana, Abugabal, Yehia I., Chamseddine, Shadi, Wietharn, Brooke, Parisi, Alessandro, Huang, Yi-Hsiang, Phen, Samuel, Vivaldi, Caterina, Salani, Francesca, Masi, Gianluca, Bettinger, Dominik, Vogel, Arndt, von Felden, Johann, Schulze, Kornelius, Silletta, Marianna, Trauner, Michael, Samson, Adel, Wege, Henning, Piscaglia, Fabio, Galle, Peter R., Stauber, Rudolf, Kudo, Masatoshi, Singal, Amit G., Itani, Aleena, Ulahannan, Susanna V., Parikh, Neehar D., Cortellini, Alessio, Kaseb, Ahmed, Rimassa, Lorenza, Chon, Hong Jae, Pinato, David J., and Pinter, Matthias

Published
2024
Full Text
View/download PDF

4. Temozolomide in Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasms: A Multicenter Retrospective Review.

Author

Chan, David, Bergsland, Emily, Chan, Jennifer, Gadgil, Rujuta, Halfdanarson, Thorvardur, Hornbacker, Kathleen, Kelly, Virginia, Kunz, Pamela, McGarrah, Patrick, Raj, Nitya, Reidy, Diane, Thawer, Alia, Whitman, Julia, Wu, Linda, Becker, Christoph, and Singh, Simron

Subjects
Capecitabine and temozolomide, Chemotherapy, Neuroendocrine tumors, Outcomes, Temozolomide, Female, Humans, Male, Middle Aged, Neoplasms, Prospective Studies, Retrospective Studies, Temozolomide
Abstract

BACKGROUND: Grade 3 gastroenteropancreatic neuroendocrine neoplasms (G3 GEPNENs) are often aggressive, and the optimal treatment is unclear for this subgroup of neuroendocrine neoplasms (NENs). Temozolomide (TEM)-based regimens have been increasingly used to treat grade 1-2 NENs, but their efficacy in G3 NENs remains undetermined. We aimed to assess the clinical efficacy of TEM-containing regimens in advanced grade 3 GEPNENs. MATERIALS AND METHODS: A multicenter retrospective review (2008-2018) of patients with metastatic/unresectable G3 GEPNENs who received a TEM-containing regimen was undertaken within a North American partnership to pool data. The primary endpoint was time to treatment failure (TTF). Radiologic response was extracted from local reports. RESULTS: One hundred and thirty patients in six high-volume NEN centers were included (median age 55, 64% male, 18% functional, 67% pancreatic NEN). Forty-nine percent were well-differentiated, 35% poorly differentiated, and 15% unknown based on local pathology reports. The regimen used was capecitabine and temozolomide (CAPTEM) in 92% and TEM alone in 8%. Radiological response by local assessment was seen in 36% of patients. Median TTF was 3.6 months and median overall survival (OS) 19.2 months. Six percent of patients required discontinuation of therapy due to adverse events. TTF was longer in first-line treatment (7.8 months vs. 2.9 months; hazard ratio, 1.62; 95% confidence interval, 1.11-2.36; p = .015) and in patients with pancreatic NENs (panNENs) compared with gastrointestinal NENs (5.8 months vs 1.8 months; p = .04). The overall response rate was higher in the first-line setting (51% vs 29%; p = .02) and in panNEN (41% vs 23%; p = .04). CONCLUSION: This is the largest TEM treatment series in G3 NEN, involving collaboration of several major North American NEN centers as a partnership. Thirty-six percent of patients showed some degree of radiographic response, and treatment was generally well tolerated, although the median duration of response was short. Response rates and time to treatment failure were superior in the first-line setting. CAPTEM should be considered a viable treatment option in this setting. Further randomized trials are warranted. IMPLICATIONS FOR PRACTICE: Neuroendocrine neoplasms (NENs) are heterogeneous, and optimal treatment for aggressive grade 3 (G3) NENs remains undetermined. The capecitabine and temozolomide (CAPTEM) regimen has been used in low-grade pancreas NENs but there are few data for its safety and efficacy in the G3 setting. This article reports on the efficacy of temozolomide-containing regimens, particularly CAPTEM, in management of G3 NENs. The good tolerance and response rate show that CAPTEM should be considered a viable regimen in treatment of G3 NENs pending confirmatory prospective studies.

Published
2021

7. THU-464 aMAP score predicts progression-free survival in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma

Author

Vithayathil, Mathew, primary, D'Alessio, Antonio, additional, Fulgenzi, Claudia, additional, Celsa, Ciro, additional, Manfredi, Giulia, additional, Nishida, Naoshi, additional, Schoenlein, Martin, additional, von Felden, Johann, additional, Schulze, Kornelius, additional, Wege, Henning, additional, Saeed, Anwaar, additional, Wietharn, Brooke, additional, Hildebrand, Hannah, additional, Wu, Linda, additional, Ang, Celina, additional, Marron, Thomas U., additional, Weinmann, Arndt, additional, Galle, Peter R., additional, Bettinger, Dominik, additional, Lin, Chun-yen, additional, Vogel, Arndt, additional, Scheiner, Bernhard, additional, Lee, Pei-Chang, additional, Huang, Yi-Hsiang, additional, Amara, Suneetha, additional, Muzaffar, Mahvish, additional, Naqash, Abdul Rafeh, additional, Zanuso, Valentina, additional, Pressiani, Tiziana, additional, Cabibbo, Giuseppe, additional, Dalbeni, Andrea, additional, Pinter, Matthias, additional, Singal, Amit, additional, Chon, Hong Jae, additional, Cortellini, Alessio, additional, Kudo, Masatoshi, additional, Rimassa, Lorenza, additional, Pinato, David J., additional, and Sharma, Rohini, additional

Published
2024
Full Text
View/download PDF

9. Immunotherapy vs Best Supportive Care for Patients With Hepatocellular Cancer With Child-Pugh B Dysfunction.

Author

Fulgenzi, Claudia Angela Maria, Scheiner, Bernhard, D'Alessio, Antonio, Mehan, Aman, Manfredi, Giulia F., Celsa, Ciro, Nishida, Naoshi, Ang, Celina, Marron, Thomas U., Wu, Linda, Saeed, Anwaar, Wietharn, Brooke, Cammarota, Antonella, Pressiani, Tiziana, Pinter, Matthias, Sharma, Rohini, Cheon, Jaekyung, Huang, Yi-Hsiang, Lee, Pei-Chang, and Phen, Samuel

Published
2024
Full Text
View/download PDF

10. Checkpoint Inhibitor-Associated Autoimmune Diabetes Mellitus Is Characterized by C-peptide Loss and Pancreatic Atrophy.

Author

Wu, Linda, Carlino, Matteo Salvatore, Brown, David Alexander, Long, Georgina Venetia, Clifton-Bligh, Roderick, Mellor, Rhiannon, Moore, Krystal, Sasson, Sarah Christina, Menzies, Alexander Maxwell, Tsang, Venessa, and Gunton, Jenny Elizabeth

Subjects
TYPE 1 diabetes, C-peptide, LIGANDS (Biochemistry)
Abstract

Objective To conduct a multicenter case series characterizing the clinical characteristics at presentation and pancreatic volume changes of patients with checkpoint inhibitor-associated autoimmune diabetes (CIADM). Research Design and Methods Electronic medical records were reviewed with 36 consecutive patients identified with CIADM, as defined by (1) previous immune checkpoint inhibitor (ICI) therapy, (2) new-onset hyperglycemia (blood glucose level ≥ 11.1 mmol/L and/or glycosylated hemoglobin ≥ 6.5%), and (3) insulin deficiency [C-peptide <0.4 nmol/L or diabetic ketoacidosis (DKA)] within 1 month of presentation. Pancreatic volume was available and measured using computed tomography volumetry for 17 patients with CIADM and 3 sets of control patients: 7 with ICI-related pancreatitis, 13 with asymptomatic ICI-related lipase elevation, and 11 ICI-treated controls for comparison. Results All patients had either anti-programmed cell death protein 1 or anti-programmed cell death ligand 1 therapy. Median time from ICI commencement to CIADM diagnosis was 15 weeks. At presentation, 25 (69%) had DKA, 27 (84%) had low C-peptide, and, by 1 month, 100% had low C-peptide. Traditional type 1 diabetes autoantibodies were positive in 15/35 (43%). Lipase was elevated in 13/27 (48%) at presentation. In 4 patients with longitudinal lipase testing, elevated levels peaked 1 month prior to CIADM diagnosis. Pancreatic volume was lower pre-ICI in CIADM patients compared with controls and demonstrated a mean decline of 41% from pretreatment to 6 months post-CIADM diagnosis. Conclusion Pronounced biochemical and radiologic changes occur during CIADM pathogenesis. Rapid loss of C-peptide is a distinct characteristic that can be used to aid diagnosis as autoantibodies are often negative. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

11. AIRPanc: A phase 2, open-label, multicenter, randomized study evaluating neoadjuvant therapy targeting the adenosine immunosuppressive pathway in combination with immune checkpoint blockade and radiation therapy in patients with advanced pancreatic ductal adenocarcinoma who are candidates for surgical resection.

Author

Manji, Gulam Abbas, primary, Labadie, Brian William, additional, Jamison, Jacob K., additional, Wu, Linda, additional, Wang, Shikun, additional, Pellicciotta, Ilenia, additional, Sta Ana, Sarah, additional, Sender, Naomi, additional, Ross, Isabelle, additional, Cho, Hope, additional, Horowitz, David Paul, additional, and Chabot, John A., additional

Published
2024
Full Text
View/download PDF

12. Contribution of neoadjuvant chemotherapy and radiation therapy (intensity-modulated radiation therapy with concurrent chemotherapy versus stereotactic body radiation therapy alone) on tumor volume regression in patients with borderline resectable or locally advanced pancreatic ductal adenocarcinoma: A single institution experience.

Author

Jamison, Jacob K., primary, Cho, Hope, additional, May, Michael S., additional, Luk, Lyndon, additional, Flusberg, Milana, additional, Kobi, Mariya, additional, Beylergil, Volkan, additional, Skorohodova, Ksenia, additional, Raufi, Alexander G, additional, Horowitz, David Paul, additional, Kluger, Michael D., additional, Pan, Samuel M, additional, Kachnic, Lisa A., additional, Schrope, Beth, additional, Bates, Susan Elaine, additional, White, Ruth Aroon, additional, Moy, Ryan H., additional, Wu, Linda, additional, Chabot, John A., additional, and Manji, Gulam Abbas, additional

Published
2024
Full Text
View/download PDF

13. The development of an ingestible biosensor for the characterization of gut metabolites related to major depressive disorder: hypothesis and theory

Author

Densil, Amanda, primary, George, Mya Elisabeth, additional, Mahdi, Hala, additional, Chami, Andrew, additional, Mark, Alyssa, additional, Luo, Chantal, additional, Wang, Yifan, additional, Ali, Aribah, additional, Tang, Pengpeng, additional, Dong, Audrey Yihui, additional, Pao, Sin Yu, additional, Suri, Rubani Singh, additional, Valentini, Isabella, additional, Al-Arabi, Lila, additional, Liu, Fanxiao, additional, Singh, Alesha, additional, Wu, Linda, additional, Peng, Helen, additional, Sudharshan, Anjana, additional, Naqvi, Zoha, additional, Hewitt, Jayda, additional, Andary, Catherine, additional, Leung, Vincent, additional, Forsythe, Paul, additional, and Xu, Jianping, additional

Published
2023
Full Text
View/download PDF

14. A meta-analysis and real-world cohort study on the sex-related differences in efficacy and safety of immunotherapy for hepatocellular carcinoma

Author

Balcar, Lorenz, primary, Scheiner, Bernhard, additional, Maria Fulgenzi, Claudia Angela, additional, D’Alessio, Antonio, additional, Pomej, Katharina, additional, Roig, Marta Bofill, additional, Meyer, Elias Laurin, additional, Cheon, Jaekyung, additional, Nishida, Naoshi, additional, Lee, Pei-Chang, additional, Wu, Linda, additional, Ang, Celina, additional, Krall, Anja, additional, Saeed, Anwaar, additional, Stefanini, Bernardo, additional, Cammarota, Antonella, additional, Pressiani, Tiziana, additional, Abugabal, Yehia I., additional, Chamseddine, Shadi, additional, Wietharn, Brooke, additional, Parisi, Alessandro, additional, Huang, Yi-Hsiang, additional, Phen, Samuel, additional, Vivaldi, Caterina, additional, Salani, Francesca, additional, Masi, Gianluca, additional, Bettinger, Dominik, additional, Vogel, Arndt, additional, von Felden, Johann, additional, Schulze, Kornelius, additional, Silletta, Marianna, additional, Trauner, Michael, additional, Samson, Adel, additional, Wege, Henning, additional, Piscaglia, Fabio, additional, Galle, Peter R., additional, Stauber, Rudolf, additional, Kudo, Masatoshi, additional, Singal, Amit G., additional, Itani, Aleena, additional, Ulahannan, Susanna V., additional, Parikh, Neehar D., additional, Cortellini, Alessio, additional, Kaseb, Ahmed, additional, Rimassa, Lorenza, additional, Chon, Hong Jae, additional, Pinato, David J., additional, and Pinter, Matthias, additional

Published
2023
Full Text
View/download PDF

15. Checkpoint inhibitor associated autoimmune diabetes mellitus is characterised by C-peptide loss and pancreatic atrophy

Author

Wu, Linda, primary, Carlino, Matteo Salvatore, additional, Brown, David Alexander, additional, Long, Georgina Venetia, additional, Clifton-Bligh, Roderick, additional, Mellor, Rhiannon, additional, Moore, Krystal, additional, Sasson, Sarah Christina, additional, Menzies, Alexander Maxwell, additional, Tsang, Venessa, additional, and Gunton, Jenny Elizabeth, additional

Published
2023
Full Text
View/download PDF

17. IL‐12/Th1 and IL‐23/Th17 biliary microenvironment in primary biliary cirrhosis: Implications for therapy

Author

Yang, Chen‐Yen, Ma, Xiong, Tsuneyama, Koichi, Huang, Shanshan, Takahashi, Toru, Chalasani, Naga P, Bowlus, Christopher L, Yang, Guo‐Xiang, Leung, Patrick SC, Ansari, Aftab A, Wu, Linda, Coppel, Ross L, and Gershwin, M Eric

Subjects
Biomedical and Clinical Sciences, Immunology, Liver Disease, Autoimmune Disease, Rare Diseases, Chronic Liver Disease and Cirrhosis, Digestive Diseases, 2.1 Biological and endogenous factors, Aetiology, Oral and gastrointestinal, Adult, Aged, Female, Humans, Immunohistochemistry, Interferon-gamma, Interleukin-12, Interleukin-23, Liver Cirrhosis, Biliary, Male, Middle Aged, Signal Transduction, Th1 Cells, Th17 Cells, Medical Biochemistry and Metabolomics, Clinical Sciences, Gastroenterology & Hepatology, Clinical sciences
Abstract

UnlabelledThe interleukin (IL)-12/IL-23-mediated Th1/Th17 signaling pathway has been associated with the etiopathogenesis of primary biliary cirrhosis (PBC). To address the cytokine microenvironment specifically in the liver, we examined the localized expression of cytokine subunits and their corresponding receptors using previously optimized immunohistochemistry with an extensive panel of antibodies directed at IL-12p70, IL-12p35, interferon-gamma (IFN-γ), IL-12RB2, IL-23p40, IL-23p19, IL-17, and IL-23R using liver from PBC (n = 51) and non-PBC (n = 80) control liver disease patients. Multiple portal tracts in each patient were blindly evaluated and individually scored. We report herein that although IL-12/Th1 and IL-23/Th17 staining was detected in all of the liver sections, they were primarily localized around the damaged interlobular bile ducts in PBC. Most important, Th17 skewing was prominent in advanced PBC patients with intensive secretion of IL-23p19 by inflamed hepatocytes around IL-23R, IL-12RB2, and IFN-γ expressing degenerated cholangiocytes. Our novel finding on the direct association of Th17 skewing and disease severity illustrates the significance of the IL-23/Th17 pathway in the perpetuation of IL-12/Th1-mediated immunopathology in PBC. Furthermore, localized IL-23p19 production by hepatocytes may enhance profibrotic Th17 signaling and proinflammatory IFN-γ production that contribute to PBC pathology.ConclusionOur data emphasize the pathogenic relevance of IL-12/Th1 and IL-23/Th17 in the evolution of PBC. Of significance, however, the shift from a Th1 to a Th17 imbalance at advanced stages of the disease suggests the necessity to consider modulation of the IL-23/Th17 pathway as a potential target for therapeutic intervention.

Published
2014

18. Efficacy and safety of atezolizumab/bevacizumab in patients with HCC after prior systemic therapy: A global, observational study

Author

Joerg, Vincent, primary, Scheiner, Bernhard, additional, D´Alessio, Antonio, additional, Fulgenzi, Claudia A.M., additional, Schönlein, Martin, additional, Kocheise, Lorenz, additional, Lohse, Ansgar W., additional, Huber, Samuel, additional, Wege, Henning, additional, Kaseb, Ahmed, additional, Wang, Yinghong, additional, Mathew, Antony, additional, Kuang, Andrew, additional, Muzaffar, Mahvish, additional, Abugabal, Yehia I., additional, Chamseddine, Shadi, additional, Phen, Samuel, additional, Cheon, Jaekyung, additional, Lee, Pei-Chang, additional, Balcar, Lorenz, additional, Krall, Anja, additional, Ang, Celina, additional, Wu, Linda, additional, Saeed, Anwaar, additional, Huang, Yi-Hsiang, additional, Bengsch, Bertram, additional, Rimassa, Lorenza, additional, Weinmann, Arndt, additional, Stauber, Rudolf, additional, Korolewicz, James, additional, Pinter, Matthias, additional, Singal, Amit G., additional, Chon, Hong Jae, additional, Pinato, David J., additional, Schulze, Kornelius, additional, and von Felden, Johann, additional

Published
2023
Full Text
View/download PDF

19. Real-world time to discontinuation of first-line venetoclax + obinutuzumab in chronic lymphocytic leukemia/small lymphocytic lymphoma

Author

Lu, Xiaoxiao, primary, Emond, Bruno, additional, Qureshi, Zaina P., additional, Wu, Linda H., additional, Forbes, Shaun P., additional, Hilts, Annalise, additional, Liu, Stephanie, additional, Lafeuille, Marie-Hélène, additional, Lefebvre, Patrick, additional, Huang, Qing, additional, and Rogers, Kerry A., additional

Published
2023
Full Text
View/download PDF

25. Individuation : an artist's quest

Author

Wu, Linda

Subjects
700
Abstract

"I use the term "individuation " to denote the process by which a person becomes a psychological "in-dividual" that is, a separate, indivisible unity or "whole ". It is generally assumed that consciousness is the whole of the psychological individual. But knowledge of the phenomena that can only be explained on the hypothesis of unconscious psychic processes makes it doubtful whether the ego and its contents are in fact identical with the "whole". If unconscious processes exist at all, they must surely belong to the totality of the individual, even though they are not components of the conscious ego. " (Jungl959:275) The above quote, defining Jung's theory of "individuation" is the principle upon which I based my art practice at the start of the Professional Doctorate programme. My quest was to create art, from conscious and unconscious elements, in other words, the totality of my personality. At that time I believed my objective was to define the archetypal phenomena with which I was concerned and having identified that, to work towards a clearer strategy for creatively expressing it within my work. The proposal I prepared at the start of the Doctorate programme highlighted an inconsistency with regard to my creative practice and the artists I admired. My paintings were abstract but I researched artists who used narrative and figuration. I resolved to reconcile this paradox by introducing narrative and figurative elements within my working practice. Initially, this proved to be more difficult in practice than I had thought and the first two years of the Doctorate programme did not see a significant change or progress in my work. There were several reasons for the delay in following through with a change in my work. Despite a conscious desire to change, will power alone was not enough to produce the hoped for transformation. I had developed a method of painting that relied on intuition to guide me to the next step and although this was not producing the desired results, I was entrenched in this methodology and found it difficult to move to a more considered way of working. Another reason for my lack of progress was my insistence on using Jungian psychological theory within my work. I was trying to summon unconscious content by using vague and obtuse references to psychological theories. I believed that if I relied on my intuition to guide me I would forge a meeting between conscious and unconscious content. I eventually managed to change from abstract to a figurative form of painting using narrative and composition. Further progress took place when I distanced myself from concentrating on psychological theory and used my life experiences to inform my work. By allowing a less illustrative way of working to develop, my paintings began to have a life of their own becoming less literal representations of ideas. The Doctorate programme enabled me to integrate the many strands of my psyche in an expanded and integrated art practice. The refinement and maturity that I believe I now demonstrate in my creative practice seemed impossible to achieve at the beginning of the programme. It was a long time before any substantive changes took place, however, it is my belief that changes that have been painstakingly won will be permanent. They are securely anchored within my psyche and therefore my art practice.

Published
2011

27. The ALBI grade refines prognostic prediction in advanced hepatocellular cancer and enables risk stratification for bleeding events following atezolizumab plus bevacizumab

Author

D’Alessio, Antonio, primary, Fulgenzi, Claudia, additional, Scheiner, Bernhard, additional, Korolewicz, James, additional, Cheon, Jaekyung, additional, Nishida, Naoshi, additional, Ang, Celina, additional, Marron, Thomas, additional, Wu, Linda, additional, Saeed, Anwaar, additional, Wietharn, Brooke, additional, Cammarota, Antonella, additional, Pressiani, Tiziana, additional, Pinter, Matthias, additional, Balcar, Lorenz, additional, Huang, Yi-Hsiang, additional, Mehan, Aman, additional, Phen, Samuel, additional, Vivaldi, Caterina, additional, Salani, Francesca, additional, Masi, Gianluca, additional, Bettinger, Dominik, additional, Vogel, Arndt, additional, Schoenlein, Martin, additional, von Felden, Johann, additional, Schulze, Kornelius, additional, Wege, Henning, additional, Samson, Adel, additional, Galle, Peter, additional, Kudo, Masatoshi, additional, Cortellini, Alessio, additional, Singal, Amit, additional, Rimassa, Lorenza, additional, Sharma, Rohini, additional, Chon, Hong Jae, additional, and Pinato, David J., additional

Published
2023
Full Text
View/download PDF

28. Efficacy and tolerability of atezolizumab and bevacizumab in patients with hepatocellular carcinoma previously treated with systemic therapy: a global, observational study

Author

Jörg, Vincent, primary, Scheiner, Bernhard, additional, D’Alessio, Antonio, additional, Fulgenzi, Claudia, additional, Schoenlein, Martin, additional, Kocheise, Lorenz, additional, Lohse, Ansgar W., additional, Huber, Samuel, additional, Wege, Henning, additional, Kaseb, Ahmed, additional, Wang, Yinghong, additional, Muzaffar, Mahvish, additional, Abugabal, Yehia, additional, Chamseddine, Shadi, additional, Phen, Samuel, additional, Cheon, Jaekyung, additional, Lee, Pei-Chang, additional, Balcar, Lorenz, additional, Krall, Anja, additional, Ang, Celina, additional, Wu, Linda, additional, Saeed, Anwaar, additional, Huang, Yi-Hsiang, additional, Bengsch, Bertram, additional, Rimassa, Lorenza, additional, Weinmann, Arndt, additional, Stauber, Rudolf E., additional, Korolewicz, James, additional, Pinter, Matthias, additional, Singal, Amit, additional, Chon, Hong Jae, additional, Pinato, David J., additional, Schulze, Kornelius, additional, and von Felden, Johann, additional

Published
2023
Full Text
View/download PDF

29. Feasibility of systemic anti-cancer therapy as an alternative to best supportive care in patients with advanced HCC and Child-Pugh B liver dysfunction

Author

Fulgenzi, Claudia, primary, D’Alessio, Antonio, additional, Scheiner, Bernhard, additional, Nishida, Naoshi, additional, Ang, Celina, additional, Marron, Thomas, additional, Wu, Linda, additional, Saeed, Anwaar, additional, Wietharn, Brooke, additional, Cammarota, Antonella, additional, Pressiani, Tiziana, additional, Pinter, Matthias, additional, Sharma, Rohini, additional, Cheon, Jaekyung, additional, Huang, Yi-Hsiang, additional, Lee, Pei-Chang, additional, Phen, Samuel, additional, Gampa, Anuhya, additional, Pillai, Anjana, additional, Napolitano, Andrea, additional, Vivaldi, Caterina, additional, Salani, Francesca, additional, Masi, Gianluca, additional, Bettinger, Dominik, additional, Thimme, Robert, additional, Vogel, Arndt, additional, Schoenlein, Martin, additional, Schulze, Kornelius, additional, von Felden, Johann, additional, Wege, Henning, additional, Galle, Peter, additional, Pirisi, Mario, additional, Park, Joong-Won, additional, Kudo, Masatoshi, additional, Rimassa, Lorenza, additional, Singal, Amit, additional, Cortellini, Alessio, additional, Chon, Hong Jae, additional, Ghittoni, Giorgia, additional, Camma, Calogero, additional, Stefanini, Benedetta, additional, Trevisani, Franco, additional, Giannini, Edoardo Giovanni, additional, and Pinato, David J., additional

Published
2023
Full Text
View/download PDF

36. Time to next treatment in patients with chronic lymphocytic leukemia initiating first-line ibrutinib or acalabrutinib.

Author

Jacobs, Ryan, Lu, Xiaoxiao, Emond, Bruno, Morrison, Laura, Kinkead, Frederic, Lefebvre, Patrick, Lafeuille, Marie-Hélène, Khan, Wasiulla, Wu, Linda H, Qureshi, Zaina P, and Levy, Moshe Yair

Abstract

Aim: To investigate real-world time to next treatment in patients with chronic lymphocytic leukemia initiating first-line (1L) ibrutinib or acalabrutinib. Materials & methods: US specialty pharmacy electronic medical records (21/11/2018–30/4/2022) were used; patients initiated 1L on/after 21/11/2019 (acalabrutinib approval). Results: Among 710 patients receiving ibrutinib, 5.9% initiated next treatment (mean time to initiation = 9.2 months); among 373 patients receiving acalabrutinib, 7.5% initiated next treatment (mean time to initiation = 5.9 months). Adjusting for baseline characteristics, acalabrutinib-treated patients were 89% more likely to initiate next treatment (hazard ratio = 1.89; p = 0.016). Conclusion: This study addresses a need for real-world comparative effectiveness between 1L ibrutinib and acalabrutinib and shows that next treatment (a clinically meaningful measure for real-world progression) occurred less frequently with 1L ibrutinib. Ibrutinib and acalabrutinib are oral medications taken once-daily and twice-daily, respectively. They are recommended as initial treatment for chronic lymphocytic leukemia (CLL). The goal of this study was to compare the efficacy of these treatments as initial treatment for CLL. To meet this goal, real-world US specialty pharmacy electronic medical records between 11/21/2018–4/30/2022 were used. Patients treated with ibrutinib or acalabrutinib as initial treatment for CLL were studied. Treatment had to be started on or after the date of acalabrutinib approval for CLL (11/21/2019). Time to next treatment was used to estimate real-world disease progression. It was defined as the time from the initiation of initial treatment with ibrutinib or acalabrutinib to the initiation of a next treatment. Study results showed that patients were observed for a median of up to 1.5 years. Over this period, next treatment was more likely for acalabrutinib (7.5%) compared with ibrutinib (5.9%). After adjusting for differences in patient characteristics, next treatment was 89% more likely with acalabrutinib than ibrutinib. This study addresses a need to compare the effectiveness of initial treatment with ibrutinib and acalabrutinib in the real-world. It helps better contextualize results from clinical trial data and shows that next treatment occurred less frequently with ibrutinib. A real-world study using US specialty pharmacy electronic medical records found that first-line patients with chronic lymphocytic leukemia initiated on acalabrutinib were 89% more likely to initiate next treatment relative to those initiated on ibrutinib. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

39. Supplementary Video 1 from A Murine Model for Quantitative, Real-Time Evaluation of Convection-Enhanced Delivery (RT-CED) Using an 18[F]-Positron Emitting, Fluorescent Derivative of Dasatinib

Author

Wang, Melinda, primary, Kommidi, Harikrishna, primary, Tosi, Umberto, primary, Guo, Hua, primary, Zhou, Zhiping, primary, Schweitzer, Melanie E., primary, Wu, Linda Y., primary, Singh, Ranjodh, primary, Hou, Shengqi, primary, Law, Benedict, primary, Ting, Richard, primary, and Souweidane, Mark M., primary

Published
2023
Full Text
View/download PDF

40. Data from A Murine Model for Quantitative, Real-Time Evaluation of Convection-Enhanced Delivery (RT-CED) Using an 18[F]-Positron Emitting, Fluorescent Derivative of Dasatinib

Author

Wang, Melinda, primary, Kommidi, Harikrishna, primary, Tosi, Umberto, primary, Guo, Hua, primary, Zhou, Zhiping, primary, Schweitzer, Melanie E., primary, Wu, Linda Y., primary, Singh, Ranjodh, primary, Hou, Shengqi, primary, Law, Benedict, primary, Ting, Richard, primary, and Souweidane, Mark M., primary

Published
2023
Full Text
View/download PDF

41. Supplementary Video 4 from A Murine Model for Quantitative, Real-Time Evaluation of Convection-Enhanced Delivery (RT-CED) Using an 18[F]-Positron Emitting, Fluorescent Derivative of Dasatinib

Author

Wang, Melinda, primary, Kommidi, Harikrishna, primary, Tosi, Umberto, primary, Guo, Hua, primary, Zhou, Zhiping, primary, Schweitzer, Melanie E., primary, Wu, Linda Y., primary, Singh, Ranjodh, primary, Hou, Shengqi, primary, Law, Benedict, primary, Ting, Richard, primary, and Souweidane, Mark M., primary

Published
2023
Full Text
View/download PDF

42. Supplementary Video S2 from A Murine Model for Quantitative, Real-Time Evaluation of Convection-Enhanced Delivery (RT-CED) Using an 18[F]-Positron Emitting, Fluorescent Derivative of Dasatinib

Author

Wang, Melinda, primary, Kommidi, Harikrishna, primary, Tosi, Umberto, primary, Guo, Hua, primary, Zhou, Zhiping, primary, Schweitzer, Melanie E., primary, Wu, Linda Y., primary, Singh, Ranjodh, primary, Hou, Shengqi, primary, Law, Benedict, primary, Ting, Richard, primary, and Souweidane, Mark M., primary

Published
2023
Full Text
View/download PDF

43. Supplementary Video 7 from A Murine Model for Quantitative, Real-Time Evaluation of Convection-Enhanced Delivery (RT-CED) Using an 18[F]-Positron Emitting, Fluorescent Derivative of Dasatinib

Author

Wang, Melinda, primary, Kommidi, Harikrishna, primary, Tosi, Umberto, primary, Guo, Hua, primary, Zhou, Zhiping, primary, Schweitzer, Melanie E., primary, Wu, Linda Y., primary, Singh, Ranjodh, primary, Hou, Shengqi, primary, Law, Benedict, primary, Ting, Richard, primary, and Souweidane, Mark M., primary

Published
2023
Full Text
View/download PDF

44. Supplementary Video 6 from A Murine Model for Quantitative, Real-Time Evaluation of Convection-Enhanced Delivery (RT-CED) Using an 18[F]-Positron Emitting, Fluorescent Derivative of Dasatinib

Author

Wang, Melinda, primary, Kommidi, Harikrishna, primary, Tosi, Umberto, primary, Guo, Hua, primary, Zhou, Zhiping, primary, Schweitzer, Melanie E., primary, Wu, Linda Y., primary, Singh, Ranjodh, primary, Hou, Shengqi, primary, Law, Benedict, primary, Ting, Richard, primary, and Souweidane, Mark M., primary

Published
2023
Full Text
View/download PDF

45. Supplementary Video 3 from A Murine Model for Quantitative, Real-Time Evaluation of Convection-Enhanced Delivery (RT-CED) Using an 18[F]-Positron Emitting, Fluorescent Derivative of Dasatinib

Author

Wang, Melinda, primary, Kommidi, Harikrishna, primary, Tosi, Umberto, primary, Guo, Hua, primary, Zhou, Zhiping, primary, Schweitzer, Melanie E., primary, Wu, Linda Y., primary, Singh, Ranjodh, primary, Hou, Shengqi, primary, Law, Benedict, primary, Ting, Richard, primary, and Souweidane, Mark M., primary

Published
2023
Full Text
View/download PDF

46. Supplementary Video 5 from A Murine Model for Quantitative, Real-Time Evaluation of Convection-Enhanced Delivery (RT-CED) Using an 18[F]-Positron Emitting, Fluorescent Derivative of Dasatinib

Author

Wang, Melinda, primary, Kommidi, Harikrishna, primary, Tosi, Umberto, primary, Guo, Hua, primary, Zhou, Zhiping, primary, Schweitzer, Melanie E., primary, Wu, Linda Y., primary, Singh, Ranjodh, primary, Hou, Shengqi, primary, Law, Benedict, primary, Ting, Richard, primary, and Souweidane, Mark M., primary

Published
2023
Full Text
View/download PDF

47. Supplementary Data from A Murine Model for Quantitative, Real-Time Evaluation of Convection-Enhanced Delivery (RT-CED) Using an 18[F]-Positron Emitting, Fluorescent Derivative of Dasatinib

Author

Wang, Melinda, primary, Kommidi, Harikrishna, primary, Tosi, Umberto, primary, Guo, Hua, primary, Zhou, Zhiping, primary, Schweitzer, Melanie E., primary, Wu, Linda Y., primary, Singh, Ranjodh, primary, Hou, Shengqi, primary, Law, Benedict, primary, Ting, Richard, primary, and Souweidane, Mark M., primary

Published
2023
Full Text
View/download PDF

48. A pilot study of gut microbiome modulation to enable efficacy of neoadjuvant checkpoint-based immunotherapy (IO) following chemotherapy in pancreatic ductal adenocarcinoma (PDAC).

Author

Wu, Linda, primary, Ang, Celina, additional, Pintova, Sofya, additional, Sung, Max W., additional, Kozuch, Peter, additional, Dharmapuri, Sirish, additional, Cohen, Noah A, additional, Schwartz, Myron E., additional, Mandeli, John P., additional, Saxena, Deepak, additional, and Cohen, Deirdre Jill, additional

Published
2023
Full Text
View/download PDF

50. Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) as prognostic biomarkers in unresectable hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (atezo-bev).

Author

Wu, Linda, primary, Fulgenzi, Claudia A.M., additional, D'Alessio, Antonio, additional, Chon, Hong Jae, additional, Kudo, Masatoshi, additional, Schönlein, Martin, additional, Felden, Johann von, additional, Wietharn, Brooke, additional, Phen, Samuel, additional, Scheiner, Bernhard, additional, Balcar, Lorenz, additional, Huang, Yi-Hsiang, additional, Pressiani, Tiziana, additional, Masi, Gianluca, additional, Naqash, Abdul Rafeh, additional, Bettinger, Dominik, additional, Vogel, Arndt, additional, Galle, Peter R, additional, Gaillard, Vince, additional, and Ang, Celina, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results